Blood cancer Archives

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed

Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […]

October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Oct 2016

It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia

The Committee on Medicinal Products for Human Use (CHMP) has handed down a pair of positive opinions of Opdivo and AbbVie’s leukemia therapy in their quests for EMA approval. Before the European Commission reviews an application for market authorization, it crosses the collective desk of the Committee on Medicinal Products for Human Use (CHMP). If […]

October 17, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Jun 2016

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma. Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO […]

June 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

cellectis cancer leukemia ucart19 car t cell therapy GOSH baby second biotech

News and Trends 9 May 2016

Universal CAR-T given to Second baby with aggressive Leukemia

Once again, the French biotech Cellectis has hit headlines after having treated a second infant suffering from an aggressive form of Leukemia with their UCART19 therapy. Also based at the famous Great Ormond Street Hospital (GOSH) in London, another child has been treated with the first ever Universal CAR-T cell therapy. The child in question […]

May 9, 2016 - 2 minutesmins - By Dani Bancroft

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing. The first therapy initially developed by […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us